chrisvoncsefalvay/vaers-outcomes huggingface dataset:
On 2/24/99, the pt received the first injection with Lymerix, with no untoward effects. On 3/24/99, he received the second dose, and for the next six months he felt achy and tired but was able to work. It was reported by 9/99 he was noted to walk with a limp and appeared fatigued. It was reported he missed work on "numerous occasions" due to pain which traveled from joint to joint. He had painful stiffness trying to get out of bed. It was reported other symptoms that were experienced included memory loss, extreme fatigue, lack of appetite, weakness, dizziness, and headaches. It was reported walking was painful, to run impossible and he was not able to perform routine tasks at work. The pt consulted a rheumatologist and had blood work which was positive for the Lyme antibody but was negative for rheumatoid factor. The rheumatology differential diagnosis included "polyarthritis in the absence of synovitis, symmetry, and a negative rheumatoid factor. The pt was treated with diclofanao which apparently was effective. "which if he forgets his symptom return. It is unclear if the pt has had a stomach and liver disorder side effects. The pt started sucralfate for his stomach.  The most recent information received on 7/12/00 inferred the symptoms are controlled by Voltaren but are ongoing. Additional information has been requested.  The pt has been persistently incapacitated as he can not perform routine tasks at work.
feels so sore today; This is a spontaneous report from a non-contactable consumer (patient) via Pfizer sales representative. A 39-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection; Batch/Lot number and expiration date were not reported), via an unspecified route of administration on 25Feb2021 as dose number unknown, single for COVID-19 immunisation. Medical history included asthma from an unknown date and unknown if ongoing. The patient's concomitant medications were not reported. The patient experienced felt "so sore" on 26Feb2021 (reported as today). The outcome of the event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
pt recvd vax & 6 months following vax pt became clumsy, & had generalized myoclonic szs each day; brain MRI scan revealed areas of inc signal in the corona radiata; EEG was abn; dec in social skills & use of language; stuporous; pneumonia;
Swelling, redness, and itching of the hand, same side as injection. Has happened once/ day for past 5 days.
Area approximately 3" x 1" slightly red at injection site. Warm to the touch and slightly itchy. After 3 days area remains pretty much the same and showing slight decrease in redness.
One or two days after inj arm sore, hot. 2 wks after 1st dose: severe chills, fever, severe headache, severe joint/muscle pains, severe backache, extreme fatigue (scale of 1-10, 12), debilitated for apprx 16 hrs; side effects lasted one wk. After 2nd dose, same side effects began the night of the injection. Same symps, but less severe (scale of 1-10, 8). Less severe symps seem to recur apprx 2-4 wks
No additional AE reported.; Expired dose of MMR II was administered to a pediatric patient today.; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender. No information on patient's medical history, current conditions and concomitant medications was provided.     On 05-JUN-2023, the patient was vaccinated with dose of expired measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) lot #U017524 and expiration date 03-JUN-2023, 0.5 milliliter for prophylaxis (route of administration, strength and dose number were not provided) (expired product administered and adverse event).
Patient went to ER approx 10-12 hrs after injection erythema/swelling/tenderness. ER diagnosed cellulitis.
This spontaneous report was received from a pharmacist concerning a patient of unknown gender and age. On an unknown date the patient was inadvertently vaccinated with ZOSTAVAX (dose, route and lot # not provided) instead of VARIVAX (Merck). No adverse effect was reported. Additional information has been requested.
On day 9 following the vaccination I noticed a red raised itchy patch at the vaccination site approximately 2 in X 2 in. No other symptoms.
Developed headache a few hours after receiving first dose. Over the subsequent days and weeks the headaches worsened. Ultimately presented to ER and was admitted with Subdural hematoma and CSF leak. Required blood patch
Information has been received from a female adult concerning herself. Around 2008 to 2010, the patient was vaccinated with ZOSTAVAX (it was reported as "shingles vaccine"). In 2013 the patient experienced shingles and it was a mild case. The shingles was showed as small silver dollar size under one arm. It only bothered/irritated her for a couple days. At the time of the report, the outcome of the event was unknown. Additional information has been requested.
PATIENT GOT HER FLU VACCINE ON 10/11/19.  HER DAUGHTER CALLED THIS AFTERNOON AND STATED THAT HER MOM DEVELOPED FEVER AND VOMITTED AFTER SHE GOT HER FLU VACCINE.  DAUGHTER SAID HER MOM IS CURRENTLY HAVING DIVERTICULITIS (BEFORE SHE GOT HER VACCINE).  I EXPLAINED  THAT THOSE SYMPTOMS MAY CAUSE BY HER CURRENT DIVERTICULITIS AND ADVISED SHE MAY TAKE SOME TYLENOL FOR FEVER.  DAUGHTER THOUGHT HER MOM WAS ALLERGIC TO THE VACCINE.
Pfizer on 3/3 and 3/24. Positive on 8/25 admitted on 8/25-current
shortness of breath; palpitations; chest heaviness; achy arms; Her son got the 2nd dose of the vaccine 22Jun2021/The patient received his first dose of the series "back around February or end of March; This is a spontaneous report from a contactable consumer or other non hcp. A 33-years-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on 22Jun2021 as single dose for covid-19 immunization. Medical history included covid-19 from an unknown date and unknown if ongoing, migraine from an unknown date and unknown if ongoing. Concomitant medication(s) included erenumab aooe (AIMOVIG) taken for migraine from an unspecified start date and ongoing. Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration around February or end of March as single dose for covid-19 immunization. The reporter reported that the patient received his first dose of the series back around February or end of March. The family then got COVID19 without going anywhere. After having the virus, he had shortness of breath with palpitations before he had the chance to get the 2nd dose of the COVID19 vaccine. Her son got the 2nd dose of the vaccine on 22Jun2021 after the pharmacy advised him, he did not need to re start the vaccine series. Since having the 2nd dose, he had "achy arms, palpitations, shortness of breath, and chest heaviness. He had an appointment with HCP that day at 15:00. Reporter also stated that the patient was also on an injectable migraine medication as well; Aimovig. Reporter noted that her other son (she has 5 children) also had similar side effects following the vaccination however not to the extent that the one she was called about that day had. The other son received his vaccine on the same day as the 33-year-old son. He had shortness of breath since having COVID and got a fever of 100.0 the day he received the shot as well as chest heaviness and shortness of breath. Reporter stated that her HCP clinic in Illinois where they go to be a very large facility, but they had no clue on anything. Reporter would like to know what the follow up care would be for her son who had experienced side effects less than 1 week following his 2nd dose of the COVID19 vaccine. The outcome of events was not recovered.  Information about lot/batch number cannot be obtained. Additional information has been requested.
After receiving the vaccine, the next day I started  to have chills overnight. On 12-30-20, I start to have some pain in my abdomen and it was very sharp pain that I have felt before because of my  history of diverticulosis. I then presented to the ER, had some imaging done and diagnosed with diverticulitis.  I was given a  10 day supply of antibiotic to take. I am doing fine right  now and received my second dose (01-18-2021) and I am feeling some discomfort in the same area of my abdomen as my first dose.
HEADACHE, CHILLS, PAIN IN JOINTS FOR 3 DAYS. I STILL HAVE HEADACHE.
Mild fever; This is a spontaneous report from a Pfizer Sponsored Program. A contactable consumer (patient himself) reported that a male patient of an unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection; Batch/Lot number, and Expiration date not reported), via an unspecified route of administration on 15May2021, as second dose, single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient experienced mild fever on an unspecified date in May2021. Patient was having a mild fever and was wondering if he could take a pain reliever. The outcome of event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Patient received COVID booster vaccination on 4/14/2022. Patient began to have shortness of breath with right sided rib pain early morning on 4/16/2022 @ 0415. Other symptoms included a cough (that was not new), and hypoxia, for which she was placed on supplemental oxygen. Shortness of breath pain worsened and patient was sent to the Hospital, where she was admitted under observation. She was diagnosed with multiple subsegmental pulmonary emboli without acute cor pulmonale, with right heart strain. She was started on Lovenox, then transitioned to Eliquis. She was discharged back to facility on 4/17/2022.
This spontaneous report was received form social medial via vendor, concerning two teenager patients of unknown age and gender.  The patients' concurrent, historical conditions and concomitant medications were not reported. On unknown dates, the patients were vaccinated with a dose of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (dosage, frequency, route of administration, lot number and expiration date, were not provided) for prophylaxis. On unspecified date, at a recent forum in San Diego, researchers presented two cases of multiple sclerosis (MS) that had developed in teenagers , on unknown dates, after receiving Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine. The outcome of the event was not reported. Upon internal review, multiple sclerosis was considered to be a medical significant event.
Information has been received from a physician via medical records concerning a male infant whose 25 year old mother with a history of 1 pregnancy and 1 live birth who was vaccinated IM with a first 0.5 ml dose of GARDASIL. The physician believed that the vaccine was given two weeks before the mother found out she was pregnant. Her LMP was 28-FEB-2009 (estimated delivery date was 05-DEC-2009). Ultrasound performed on 31-JUL-2009 showed normal result. On 24-NOV-2009 the mother was admitted for delivery. On 25-NOV-2009, at 08:20, the mother delivered a normal male neonate via spontaneous vaginal delivery. The baby's birth weight was 7 pounds and 14.25 ounces, length was 20 inches, chest circulation was 13.25 and head circulation was 13.5. The Apgar score was 9 at 1 minute and 9 at 5 minutes. The baby passed the hearing screen. Physical examination showed Mongolian spots sacrum, mild caput molding, positive bilateral retinal reflex, regulator rhythm and rate, no murmur, descended testes and no hip dislocate. On 26-NOV-2009 the mother and the baby were discharged from the hospital and discharge examination showed the baby had jaundice face. On 30-NOV-2009 the baby was seen for a newborn check. The baby had breast feeding, using Similac formula with iron. Physical examination showed skin jaundice (to xiphoid) and slight icteric in eyes. The assessment was healthy newborn and continued the current feeding regimen. On 22-DEC-2009 the baby was seen for a well child visit. Baby's father complained of possible cross eyed of the baby. Physical examination showed no significant strabismus. The doctor's assessment was normal occasionally strabismus and expected resolution over the next few months. On 26-JAN-2010 the baby was seen for a well child visit and physical examination revealed no abnormalities. The doctor's assessment was healthy 2 month old male baby. At the visit, the baby received the first dose of PED/ADOL-PRESERV FREE, pneumococcal and rotavirus, pentavalent RV5. Mongolian spots sacrum was considered a congenital anomaly. The mother's experience is reported in WAES 0907USA00684. Additional information has been requested. All medical records will be provided upon request.
Eye inflammation in both the eyes; Eyes got red; Pain in the back of right eye over to ear; Swollen lymph nodes; This spontaneous case was reported by a consumer and describes the occurrence of EYE INFLAMMATION (Eye inflammation in both the eyes), OCULAR HYPERAEMIA (Eyes got red), EYE PAIN (Pain in the back of right eye over to ear) and LYMPHADENOPATHY (Swollen lymph nodes) in a 44-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In 2021, the patient experienced EYE INFLAMMATION (Eye inflammation in both the eyes), OCULAR HYPERAEMIA (Eyes got red), EYE PAIN (Pain in the back of right eye over to ear) and LYMPHADENOPATHY (Swollen lymph nodes). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at a dose of UNK dosage form. At the time of the report, EYE INFLAMMATION (Eye inflammation in both the eyes), OCULAR HYPERAEMIA (Eyes got red), EYE PAIN (Pain in the back of right eye over to ear) and LYMPHADENOPATHY (Swollen lymph nodes) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.  it was reported that, patient was prescribed to take Lotemax, and MRI (magnetic resonance imaging).
My arm is still red (but fading) where the shot was administered-2 weeks later. The redness is about 1/2 inch diameter and has a crusted cover. No pain is associated with it when first observed on 1/18/10 it was bright red and weepy. Two hours after receiving the shot. I felt somewhat nauseous-lasted only 5-10 minutes.
This is a spontaneous report from a contactable pharmacist through a non-clinical study program. A 65 years old female patient received on 06Nov2014 PREVNAR 13 (lot number J90092, expiration date May2016, NDC number: 00005197105) at 0.5 ml single, intramuscular. Medical history and concomitant medications were not reported. On 06Nov2014 the patient experienced redness around the site (it site was about 6 inches long and 3 inches wide). The vaccination site was hot too since an unspecified date in Nov2014. The patient was not recovered from vaccination site redness, while vaccination site warmth outcome was unknown. Follow-up (10Jan2015): Follow-up attempts completed. No further information expected.
Dizziness, Headache, SkinRash, Rash,  ErythemaMultiform, NauseaVomiting & Tachycardia Narrative:
She reports symptoms of chest pressure, dry mouth, abrupt feeling of not well.  Treatment/intervention Patient placed on transport cart, BP 180/103, HR 110, 97% on RA. RRT called. 3 lead telemetry monitor placed on patient. Patient transported to ED with belongings by cart.
Vaccine given outside of indicated age range at community vaccine POD. Patient not displaying any adverse signs/symptoms.
Patient returned to clinic 05/29/14 at 3:00pm with a localized reaction to Left arm, redness and swelling, ecchymosis, warm to touch, 30mm diameter. Patient stated pain to the area and it started the morning after receiving the vaccine. Denies any other symptoms. Advised to take ibuprofen, Benadryl and cold compress to area. Also to follow up with primary care provider.
pain in left arm /very painful/ it is not going well; can't use the left arm; the pain is now going to her fingers; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (pain in left arm /very painful/ it is not going well), HYPOKINESIA (can't use the left arm) and PAIN IN EXTREMITY (the pain is now going to her fingers) in a 49-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   In June 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (pain in left arm /very painful/ it is not going well), HYPOKINESIA (can't use the left arm) and PAIN IN EXTREMITY (the pain is now going to her fingers). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency and IBUPROFEN for Adverse event, at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (pain in left arm /very painful/ it is not going well) had not resolved and HYPOKINESIA (can't use the left arm) and PAIN IN EXTREMITY (the pain is now going to her fingers) outcome was unknown. Not Provided          No relevant concomitant medications were reported. The patient had pain in the left arm after the second shot. can't use the left arm, it was very painful, and it was not going well. The pain was now going to her fingers. Friend got the first shot in June, and second shot days later (reporter said the expected interval for second shot). The patient had been taking medication to treat symptoms, and it alleviates for a time, but then the pain comes back.  Treatment medication included Tylenol (it is not helping), ibuprofen, it also doesn't help.
Swollen tongue and throat with fine rash over entire body beginning within hour of vaccination and continuing until 10 PM with 3 doses of 250 mg of benadryl.  Pt. did not seek medical attention for AE.
DIZZINESS, BLUE LIPS, LOSS OF CONSCIOUSNESS, NAUSEA UPON REGAINING CONSCIOUSNESS. MOVED TO FLOOR, ROUSED AWAKE, DRANK WATER, MONITORED, CALLED EMS.
4/28/23 rash noted at R thigh injection site 4/29/23 pt. c/o itching at R thigh site but area appeared normal 4/30/23 pt. awoke with quarter sized lesion that increased in size over 6 hours to a large 3-4 inch circle area. Hot to touch, red and swollen. 5/1/23 Area became enlarged outside the marked circle 5/2/23 Bruising along with the redness, heat and swelling
25 year old patient presented on 23 OCT 2007 with 4 week history of polyuria and polydipsia. Patient reports weight loss of 20-30 pounds over previous 12 months. His glucose level was 413, his HbgA1c 10.4, his CO2 was 28, and his urine was 1+ for ketones. He was diagnosed with Type 2 DM and started on glipizide along with diet modification, and later Metformin, as well as ACTOS and Insulin. In NOV 2007, patient was referred to a Endocrinologist who, in early DEC 2007, felt patient most likely had Latent Autoimmune Diabetes in Adults (LADA), although his blood sugars were controlled with oral agents. In DEC 2007, he tested antibody positive for GAD65 and Islet Cell antibodies and his C-peptide level was 4.2. Patient denies a history of elevated glucose or blood pressure levels or history of hypertension prior to DM diagnosis. He exercised regularly and had a normal BMI (24) at time of diagnosis. Patient has no first degree family members with a history of diabetes. He denies experiencing any congestion, cough, fever, sinus pain, or diarrhea in weeks-months prior to diagnosis.
30 minutes after receiving the vaccine the patient developed hives, scratchy eyes, and a scratchy throat. He reported to the ED and was given Benadryl, methylprednisolone, and famotidine. His symptoms resolved and he was shortly thereafter discharged.
Fever 103, cloudy mentation, dizziness and redness at site of immunization.
Information has been received from a physician concerning a 65 year old male with neuropathy, hypertension, hyperlipidaemia and allergies to rofecoxib (WAES # 0704USA05632), statins and codeine, who on 16-APR-2007 was vaccinated SC with a 0.5 ml dose of Zostavax (lot # 656861/0329U). Concomitant therapy included Diovan, aspirin and vitamin B complex. On 16-APR-2007 the patient developed extreme neuropathic pain and numbness to his hands and feet after vaccination. He also reported tinnitus. Unspecified medical attention was sought. There were no lab or diagnostic tests performed. At the time of the report the patient had not recovered. There was no product quality complaint involved. The patient's events were considered disabling. Additional information has been requested.
foot infection; Almost 8 weeks since first dose (missed second dose); This spontaneous case was reported by a consumer and describes the occurrence of LOCALISED INFECTION (foot infection) in a 70-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event (No reported medical history).    On 22-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Mar-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Almost 8 weeks since first dose (missed second dose)). On an unknown date, the patient experienced LOCALISED INFECTION (foot infection) (seriousness criterion hospitalization). The patient was hospitalized on 11-Feb-2021 due to LOCALISED INFECTION. The patient was treated with Wound care (Hyperbaric Oxygen Chamber Therapy) for Localised infection. On 23-Mar-2021, PRODUCT DOSE OMISSION ISSUE (Almost 8 weeks since first dose (missed second dose)) had resolved. At the time of the report, LOCALISED INFECTION (foot infection) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment for the event, localized infection included antibiotics.   Reporter did not allow further contact; Sender's Comments: This case concerns a 70-year-old male hospitalized with a serious unexpected event of localised infection in his foot, also with a nonserious unexpected event of product dose omission issue.  Event onset 2 months and 2 days after first dose mRNA-1273. Treated with antibiotics. Event resolving. Based on current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Fainted 5 seconds, sweating, loss vision - BP 102/58; HR 68, RR 16 -- > 104/60; HR 89